Alemtuzumab-Induced Hemophilia A in MS

Alemtuzumab induced acquired hemophilia A in multiple sclerosis: a case report

This case report highlights a rare instance of acquired hemophilia A induced by alemtuzumab in a patient with multiple sclerosis. Alemtuzumab, a disease-modifying therapy, is effective for relapsing MS but can trigger severe immune-mediated side effects, including this rare bleeding disorder. Early diagnosis and targeted management are critical to addressing this complication while balancing MS treatment. The report underscores the importance of monitoring patients for atypical immune responses during alemtuzumab therapy.